🇨🇳 China Health News: AI Drug Discovery Startup Anew Labs Raises $290 Million
Shanghai, September 22, 2026: China’s artificial-intelligence healthcare sector has attracted major new investment after Anew Labs, a Shanghai-based company focused on AI-powered drug discovery, completed a $290 million funding round following its separation from technology company ByteDance. The fundraising values the company at approximately $1.5 billion, according to people familiar with the transaction cited by Reuters.
AI moves deeper into pharmaceutical research
Anew Labs is developing artificial-intelligence technologies designed to support pharmaceutical and biological research. Its work includes computational tools for biomolecular structure prediction and molecular design, areas that could help researchers investigate potential medicines more efficiently.
The company emerged from ByteDance’s AI drug-discovery activities and is now operating as a separate business. Despite the spin-off, ByteDance is expected to retain a 56% stake following the fundraising round.
Major investors back the company
The funding round attracted several prominent investment firms. Reuters reported that the financing involved investors including HSG, IDG Capital and Hillhouse, with 5Y Capital also participating as a co-lead investor.
The scale of the investment highlights the growing financial interest in companies attempting to combine AI with pharmaceutical research.
China strengthens broader pharmaceutical innovation
Anew Labs’ fundraising comes as Chinese authorities are also seeking to strengthen the country’s pharmaceutical innovation ecosystem.
China’s National Medical Products Administration said on September 20 that the country had approved 59 innovative drugs and 51 innovative medical devices for market launch during 2026 so far. Authorities have announced plans to accelerate approvals for innovative medicines and medical devices while strengthening support for pharmaceutical research and development.
China also plans to strengthen protection for clinical-trial data and introduce market-exclusivity measures for certain pediatric and rare-disease medicines. Regulators say the measures are intended to provide greater certainty for companies investing in new drug development.
AI does not eliminate the drug-development process
Although AI can help researchers analyse biological information and identify potential candidates, an AI-generated drug candidate still has to pass laboratory research, clinical testing and regulatory review before it can become an approved treatment.
That means the new investment is primarily an investment in research and development capabilities, rather than an indication that new AI-designed medicines are immediately available to patients.
A growing global trend
The development reflects a broader international trend in which technology companies and biotechnology firms are increasingly using AI for drug discovery.
Anew Labs joins a growing group of specialised AI-biotech companies seeking to use computational models to address some of the most time-consuming stages of pharmaceutical research. China’s expanding investment in this field could further increase competition in the global AI-driven drug-discovery market.
For patients, the potential long-term significance will depend on whether these technologies can ultimately produce safe, effective medicines that successfully pass clinical and regulatory evaluation.
